Revolutionary Non-Invasive Cancer Detection Method

  • Guardant Health’s colorectal cancer blood test gets FDA approval
  • Test approved as primary screening option
  • First blood test for colorectal cancer with Medicare reimbursement eligibility
  • Available for adults aged 45 and older at average risk

Guardant Health announced that its colorectal cancer blood test, known as Shield, has received approval from the Food and Drug Administration (FDA) for use as a primary screening option. This makes it the first blood test for this type of cancer to meet Medicare reimbursement requirements. The test is now available for adults aged 45 and older who are at average risk for colorectal cancer, allowing healthcare providers to offer Shield in a similar manner to other non-invasive screening methods recommended by guidelines.

Factuality Level: 10
Factuality Justification: The article provides accurate and concise information about the FDA approval of Guardant Health’s colorectal cancer blood test, its eligibility for Medicare reimbursement, and its availability to adults age 45 and older at average risk. It also mentions that healthcare providers can offer it as a non-invasive screening option.
Noise Level: 3
Noise Justification: The article provides relevant information about the FDA approval of Guardant Health’s colorectal cancer blood test and its availability for Medicare reimbursement. It also mentions the target population for the test. However, it lacks in-depth analysis or exploration of the implications of this development.
Public Companies: Guardant Health (GH)
Key People: Michael Susin (Author)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: The approval of Guardant Health’s colorectal cancer blood test may impact the healthcare and medical technology sectors, as well as potentially affecting the revenue of competitors in the market.
Financial Rating Justification: This article discusses the FDA approval of a new medical test, which can affect the financial performance of companies involved in the healthcare and medical technology industries. Additionally, it mentions Medicare reimbursement, which is related to financial aspects of healthcare.
Presence Of Extreme Event: No
Nature Of Extreme Event: Other
Impact Rating Of The Extreme Event: Minor
Extreme Rating Justification: There is no extreme event mentioned in the article. The FDA approval of a colorectal cancer blood test is significant, but it doesn’t meet the criteria for an extreme event as defined by the given categories.

Reported publicly: www.marketwatch.com